Among its findings, the report notes:
1. The global market for gastrointestinal drugs reached $35.7 billion in 2015.
2. The market is expected to reach $48.4 billion by 2022, growing at a CAGR of 4.45 percent.
3. At present, AbbVie is leading the market; however, Takeda Pharmaceutical is expected to be the leading market player by the end of 2022.
4. Other key market players include Johnson & Johnson, Allergan and AstraZeneca.
5. GBI Research says that this increase in market value is, in part, due to a growing interest in biologic products.
More articles on gastroenterology and endoscopy:
Cologuard included in 2017 HEDIS quality measures for CRC screening: 4 notes
Allergan buys rights to AstraZeneca’s IBD treatment drug for $250M: 3 notes
Global market for endoscopic devices to grow at 7.06% CAGR until 2020: 5 notes
